CD44 and neoplasm: Both OB-RES and DIO therapy-treated mice displayed a significant increase in CD44+CD4+ TILs at day 27–28 compared to no therapy controls, likely due to tumor-induced reductions in the CD44+CD4+ TIL population that occurred in the absence of therapy.